BioSpace News Archive

Innate Pharma SA announced that it will host a virtual investor event on Wednesday, June 23, 2021, at 2 p.m. CEST / 8 a.m. EDT.

The global laboratory chemical reagents market is estimated to show growth at prodigious pace during the assessment period of 2020 to 2030.

Emergence of new liner materials such as polyurethane and thermoplastic elastomer pushing the sales of the prosthetic liners market

The antifungal drugs market is a very successful over-the-counter drug segment, in which robust generic competition is slated to rake in almost 65% to 70% of total market revenues in the near future.

Center will contribute to national prioritization of clinical effectiveness through understanding patients as individuals in personalized cancer care.

Fractyl Health, a life sciences company dedicated to developing novel therapeutic interventions aimed at reversing the metabolic disease epidemic, announced the closing of a $100 million Series F financing.

SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, reported the initiation of a Phase 1/2 clinical trial to evaluate mirdametinib, an investigational MEK inhibitor, for the treatment of children, adolescents, and young adults with low-grade glioma.

Centogene N.V., a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, announced financial results for the first quarter ended March 31, 2021.

Epizyme, a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, launched the EZH2Now Testing Program, an Epizyme initiative in collaboration with Quest Diagnostics, the leading provider of diagnostic information services, to provide EZH2 mutation testing for patients with relapsed or refractory follicular lymphoma.

BioCryst Pharmaceuticals, Inc. today announced that the Israeli Ministry of Health has accepted the regulatory submission of ORLADEYO for the prevention of recurrent attacks in patients with hereditary angioedema (HAE).